Literature DB >> 14605181

Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.

M C Serrano1, D Morilla, A Valverde, M Chávez, A Espinel-Ingroff, R Claro, M Ramírez, E Martín Mazuelos.   

Abstract

We compared the Etest with a broth microdilution method, performed according to a modified National Committee for Clinical Laboratory Standards guideline (M38-A), for determining the in vitro susceptibility of 77 isolates of Aspergillus spp. (26 A. fumigatus, 21 A. flavus, 10 A. terreus, 9 A. niger, 5 A. nidulellus, 4 A. glaucus, and 2 A. flavipes isolates). Overall, there was 92.2% agreement between both methods when Etest MICs were read at 24 h and 83.1% agreement when both methods were read at 48 h. When Etest MICs were read at 24 h, the agreement was >90% for all species tested except for A. fumigatus (84.6%). When Etest MICs were read at 48 h, the agreement ranged from 50 to 100%. The poorest agreement was seen with A. glaucus (50%) and A. fumigatus (65%). Where a discrepancy was observed between Etest and the reference method, the Etest MIC was generally higher. The Etest appears to be a suitable alternative procedure for testing the susceptibility of Aspergillus spp. to voriconazole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605181      PMCID: PMC262461          DOI: 10.1128/JCM.41.11.5270-5272.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

Review 1.  Therapeutic outcome in invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

2.  E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

Authors:  Ana Espinel-Ingroff; A Rezusta
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors:  M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

Authors:  S A Radford; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.

Authors:  O Uzun; S Arikan; S Kocagöz; B Sancak; S Unal
Journal:  Diagn Microbiol Infect Dis       Date:  2000-10       Impact factor: 2.803

8.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

9.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors:  A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.

Authors:  Erja Chryssanthou; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

View more
  5 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 2.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

3.  Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds.

Authors:  Frédéric Lamoth; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

4.  Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp.

Authors:  Carmen Castro; M Carmen Serrano; Bernardo Flores; Ana Espinel-Ingroff; Estrella Martín-Mazuelos
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

Review 5.  Antifungal Susceptibly Testing by Concentration Gradient Strip Etest Method for Fungal Isolates: A Review.

Authors:  Eric Dannaoui; Ana Espinel-Ingroff
Journal:  J Fungi (Basel)       Date:  2019-11-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.